Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02439957
Recruitment Status : Terminated (Study terminated early due to results from another CMX001 study.)
First Posted : May 12, 2015
Results First Posted : July 16, 2021
Last Update Posted : July 16, 2021
Sponsor:
Information provided by (Responsible Party):
Chimerix

Brief Summary:
This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease in CMV-seropositive kidney transplant recipients who received antilymphocyte induction therapy.

Condition or disease Intervention/treatment Phase
Cytomegalovirus Disease Kidney Transplant Infection Drug: Brincidofovir Drug: Valganciclovir Phase 3

Detailed Description:
This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease in CMV-seropositive kidney transplant recipients who received antilymphocyte induction therapy. The study comprised a screening evaluation period (up to 14 days posttransplant), a treatment period (up to 14 weeks posttransplant), and a posttreatment follow-up period (10 weeks, through Week 24 posttransplant).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Study to Assess Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in CMV-Seropositive Kidney Transplant Recipients Who Received Antilymphocyte Induction Therapy
Actual Study Start Date : September 2015
Actual Primary Completion Date : May 15, 2016
Actual Study Completion Date : July 31, 2016


Arm Intervention/treatment
Active Comparator: Treatment 1
100 mg brincidofovir (BCV; one 100 mg tablet) twice weekly plus valganciclovir (vGCV) placebo (2 tablets) once daily.
Drug: Brincidofovir
Other Names:
  • BCV
  • CMX001

Active Comparator: Treatment 2
900 mg valanciclovir (vGCV; two 450 tablets) once daily plus brincidofovir (BCV) placebo (1 tablet) twice weekly.
Drug: Valganciclovir
Other Name: vGCV




Primary Outcome Measures :
  1. The Incidence of Cytomegalovirus (CMV) Disease [ Time Frame: 24 weeks (±14 days) ]

    The incidence of CMV disease, which included CMV tissue-invasive disease and CMV syndrome, occurring anytime between randomization and Week 24 posttransplant (±14 days).

    The proportion of subjects who met this failure endpoint were to be compared between brincidofovir (BCV) and valganciclovir (vGCV) using an unadjusted 95% confidence interval (CI) of the absolute difference between groups (BCV minus vGCV). Number of failures and failure rates were to be presented for each treatment. If the upper bound of the 95% CI fell below 10%, BCV would have demonstrated non-inferiority to vGCV. In the event that the upper bound of the 95% CI fell below 0%, BCV would have additionally demonstrated superiority over vGCV.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Subjects must have met all of the following criteria, as applicable, to be eligible to participate in this study:

  1. Were male or female kidney transplant recipients who were ≥18 years of age (subject to local law/practice for clinical trial participation) and ≤14 days following their first or second renal allograft.
  2. Were at high risk of cytomegalovirus (CMV) infection, which for the purposes of this study, was defined as CMV-seropositive recipients who received lymphocyte depleting induction treatment with antithymocyte globulin (Thymoglobulin® or Atgam®) prior to or during the qualifying transplant.
  3. Had an estimated glomerular filtration rate of >10 mL/min (Cockcroft-Gault equation) at screening based on local laboratory results.
  4. Were CMV viremia negative (i.e., "not detected") as measured by the designated central virology laboratory using the Roche COBAS® AmpliPrep/COBAS® TaqMan® CMV Test no more than 5 days prior to subject randomization, and at all prior assessments performed since transplant under local standard of care.
  5. Were able to ingest, absorb, and tolerate tablets.
  6. If male, was willing to use an acceptable contraceptive method(s) throughout the duration of his participation in the study, i.e., through Week 24.
  7. If female of childbearing potential, i.e., not postmenopausal or surgically sterile, was willing to use 2 acceptable contraceptive methods, 1 of which must have been a barrier method, throughout the duration of her participation in the study, i.e., through Week 24.
  8. Were willing and able to provide informed consent.
  9. Were willing and able to participate in all required study activities for the entire duration of the study (i.e., through Week 24).

Exclusion Criteria

Subjects who met any of the following criteria were not eligible to participate in this study:

  1. Weighed ≤50 kg (110 lbs) or ≥120 kg (265 lbs).
  2. Were pregnant or breastfeeding or intended to conceive during the study period (i.e., through Week 24).
  3. Received a stem cell transplant or solid organ transplant other than a kidney transplant.
  4. Had suspected CMV disease (either syndrome or tissue-invasive disease) or detectable CMV viremia by the central virology laboratory prior to the first dose of study drug.
  5. Had a history of CMV disease (either syndrome or tissue-invasive disease) within 6 months prior to the first dose of study drug.
  6. Had an absolute neutrophil count of < 500 cells/μL, platelet count of < 25,000 platelets/μL, or hemoglobin of < 8 g/dL at screening.
  7. Had hypersensitivity (not including renal dysfunction or an eye disorder) to valganciclovir (vGCV), ganciclovir (GCV), cidofovir (CDV), or brincidofovir (BCV) or their excipients.
  8. Had received (or who are anticipated to need treatment with) any of the following:

    • GCV, vGCV, foscarnet, intravenous CDV, or any other anti-CMV therapy (including CMV immune globulin, cell-based therapies, and investigational anti-CMV drugs, e.g., leflunomide, letermovir [previously AIC246], or maribavir) at any time posttransplant;
    • Any anti-CMV vaccine at any time;
    • Any other investigational drug within 14 days prior to the first dose of study drug (unless prior approval had been received from the Chimerix Medical Monitor or designee); or
    • Prior treatment with BCV at any time. [Note: An "investigational drug" was defined as any drug that was not approved for any indication by the FDA (or appropriate regulatory authority).]
  9. Received acyclovir (ACV) orally at >2000 mg total daily dose (TDD) or intravenously at >15 mg/kg TDD, valacyclovir (vACV) at > 3000 mg TDD on the first dose of study drug or were anticipated to receive any of these drugs at the doses described after the first dose of study drug.
  10. Were infected with HIV, hepatitis B virus (HBV), and/or hepatitis C virus (HCV), had evidence of active viral replication within 6 months prior to screening, as demonstrated by detectable HIV or HCV RNA, or detectable HBV DNA in blood, plasma or serum.
  11. Had severe vomiting, diarrhea or malabsorption syndrome on or prior to the first dose of study drug.
  12. Had gastrointestinal (GI) disease that would have, in the judgment of the investigator, precluded the subject from taking or absorbing oral medication (e.g., gastroparesis, diabetic autonomic neuropathy affecting the GI tract, clinically active Crohn's disease, ischemic colitis, moderate or severe ulcerative colitis, small bowel resection, ileus, or any condition expected to require abdominal surgery during the course of study participation).
  13. Had serum alanine aminotransferase or aspartate aminotransferase concentrations >5 x the upper limit of normal (ULN).
  14. Had total serum bilirubin >2 x the ULN and direct bilirubin >1.5 x the ULN.
  15. Had moderate (Class B) to severe (Class C) hepatic dysfunction according to the Child-Pugh Turcotte scoring system.
  16. Received or would require digoxin or ketoconazole therapy (other than topical formulations) during the treatment phase of the study.
  17. Had active malignancies (with the exception of basal cell carcinoma).
  18. Had a serious psychiatric, medical disorder, including abnormal laboratory values, that would have, in the judgment of the investigator, put the subject at increased risk by participating in the study, or would have interfered with the conduct of study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02439957


Locations
Layout table for location information
United States, California
St. Vincent Medical Center
Los Angeles, California, United States, 90057
United States, Colorado
University of Colorado Hospital/Health Science Center
Aurora, Colorado, United States, 80045
United States, Connecticut
Yale New Haven Hospital
New Haven, Connecticut, United States, 06520
Sponsors and Collaborators
Chimerix
Layout table for additonal information
Responsible Party: Chimerix
ClinicalTrials.gov Identifier: NCT02439957    
Other Study ID Numbers: CMX001-307
First Posted: May 12, 2015    Key Record Dates
Results First Posted: July 16, 2021
Last Update Posted: July 16, 2021
Last Verified: June 2021
Keywords provided by Chimerix:
Cytomegalovirus
CMV
Additional relevant MeSH terms:
Layout table for MeSH terms
Cytomegalovirus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Infections
Valganciclovir
Brincidofovir
Antiviral Agents
Anti-Infective Agents